IV stem cell infusion in HF patients brings improved health status, functional capacity, but not improved cardiac function
National Institutes of Health, PCORI and European Union; and is a consultant to Amgen, Bayer, Cardiocell, Novartis, Boehringer-Ingelheim, Relypsa, Z Pharma, PharmaIn, SC Pharma and Gilead.
August 28, 2016 Conference Reports
The premise was that stem cells may have immune modulatory properties, which are enhanced when grown under hypoxic conditions,” explained lead author Javed Butler MD, MPH, FACC, FAHA, MBA, division chief, cardiology,Stony Brook University, Stony Brook, NY, USA. “Virtually all previous studies of stem cell therapy for heart failurehave centered on the concept that the cells must be injected directly into the heart to trigger new growth, but if stem cells have anti-inflammatory benefits, direct cardiac delivery may not be necessary to repair and stimulate thedysfunctional viable myocardium.
To our knowledge, this trial represents the first experience with intravenously administered itMSCs in patients withany type of chronic cardiomyopathy. Further studies should explore the efficacy of serial dosing to produce more sustained immunomodulatory effects and thereby perhaps facilitate improvement in left ventricular structure andfunction, and in clinical outcomes,” concluded Dr. Butler.